OrbusNeich has announced that Genous stent has attained positive clinical and safety outcomes in a 12-month follow-up data in patients discontinuing dual antiplatelet therapy (DAPT) at 30 days and at six months.
Genous stent utilises the company’s patented endothelial progenitor cell (EPC) capture technology to speed-up the natural healing of the vessel wall after the implantation of blood-contact devices.
The 12-month follow-up study assessed patient outcomes from e-HEALING, a multi-center worldwide prospective clinical registry that involved 4,939 patients with at least one lesion suitable for non-urgent percutaneous coronary intervention (PCI) and Genous stent implantation.
The trial showed that Target vessel failure (TVF) was 6.5% in patients continuing DAPT at 30 days compared to 6.3% in patients who stopped at 30 days and 2.4% in patients continuing DAPT at six months versus 2.9% in patients who stopped at six months.
Academic Medical Center in Amsterdam professor Peter Damman said studies reported that early discontinuation of DAPT after the placement of a drug eluting stent is associated with higher rates of stent thrombosis.
”These results reaffirm the safety and efficacy of the Genous stent when accompanied by only one month of DAPT and support the use of Genous as an alternative to drug eluting stents in cases where DAPT may need to be stopped early after stenting," Damman added.